Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD). The GLycopyrronium bromide in COPD airWays clinical Study 2 (GLOW2) evaluated the efficacy and safety of NVA237 in moderate-to-severe COPD over 52...

Full description

Bibliographic Details
Main Authors: Kerwin, Edward, Hébert, Jacques, Gallagher, Nicola, Martin, Carmen, Overend, Tim, Alagappan, Vijay K.T., Lu, Yimeng, Banerji, Donald
Format: Online
Language:English
Published: European Respiratory Society 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485572/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485572/

Similar Items